 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Clinical Pharmacist, Shands Jacksonville, Jacksonville, FL
Clinical Assistant Professor, College of Pharmacy, The Ohio State University, Columbus, OH
Clinical Assistant Professor, College of Pharmacy, The Ohio State University
Reprints: Dr. Patel, Shands Jacksonville, 655 W. 8th St., Jacksonville, FL 32209-6511, fax 904/244-4998, Harita_patel{at}hotmail.com
BACKGROUND: Chronic kidney disease (CKD) poses significant public health concerns. Early identification and interventions can help prevent or slow progression to end-stage renal disease.
OBJECTIVE: To characterize CKD in high-risk indigent patients in a primary care setting and evaluate opportunities for pharmacists to work collaboratively with physicians to improve medication use and CKD patient outcomes.
METHODS: Medical records of 200 patients with diabetes mellitus and/or hypertension were reviewed by the clinical pharmacist. Estimated glomerular filtration rate (creatinine clearance [Clcr]) and urinalysis were used to identify and stage CKD according to published guidelines. Glycosylated hemoglobin concentrations and blood pressures were recorded. The pharmacist evaluated medications for possible drug-related problems (DRPs), made therapeutic recommendations, and evaluated the acceptance rate by physicians.
RESULTS: One hundred nineteen patients met inclusion criteria, and a total of 68.9% met CKD criteria: stage 1, 16.0%; stage 2, 20.2%; stage 3, 25.2%; stage 4, 1.7%; stage 5, 0.8%; and not stageable, 5.0%. A total of 381 DRPs were identified, averaging 3.2 (1.7) per patient (range 0-11). The number of DRPs correlated with Clcr (r = -0.25; p = 0.007). Therapeutic recommendations included change of drug, dose and/or interval adjustment of the current drug, discontinuation of nonsteroidal antiinflammatory drugs, additional laboratory monitoring, meeting goal blood pressure and glycosylated hemoglobin, adding renoprotective drug and/or low-dose aspirin, and nephrologist referral. Fewer than half (40.9%) of the recommendations were accepted or accepted with modifications, and an approximately equal percentage were not accepted by the physicians.
CONCLUSIONS: CKD prevalence was high among the patients evaluated here. New guidelines are available to assist in managing CKD ambulatory patients. Pharmacist collaboration with physicians may optimize CKD screening in high-risk patients and improve medication usage.
Key Words: ambulatory care, chronic kidney disease, National Kidney Foundation
Published Online, November 16, 2004. www.theannals.com, DOI 10.1345/aph.1E269
This article has been cited by other articles:
|
|
 |
|
  M. S Joy and G. R Matzke Nephrology Pharmacy: Historical Reflections and Future Challenges Ann. Pharmacother., November 1, 2007; 41(11): 1884 - 1886. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tomlinson How Do We Re-Design the Treatment?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_9): ix39 - ix44. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Halbesma, D.-S. Kuiken, A. H. Brantsma, S. J.L. Bakker, J. F.M. Wetzels, D. De Zeeuw, P. E. De Jong, R. T. Gansevoort, and for the PREVEND Study Group Macroalbuminuria Is a Better Risk Marker than Low Estimated GFR to Identify Individuals at Risk for Accelerated GFR Loss in Population Screening J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2582 - 2590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shah, J. Dowell, and S. Greene Evaluation of Clinical Pharmacy Services in a Hematology/Oncology Outpatient Setting Ann. Pharmacother., September 1, 2006; 40(9): 1527 - 1532. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
